Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.

TitlePolyclonal antibody responses to HIV Env immunogens resolved using cryoEM.
Publication TypeJournal Article
Year of Publication2021
AuthorsAntanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J, Bastidas R, LaBranche C, Allen JD, Copps J, Perrett HR, Rantalainen K, Cannac F, Yang YR, de la Peña ATorrents, Rocha RFroes, Berndsen ZT, Baker D, King NP, Sanders RW, Moore JP, Crotty S, Crispin M, Montefiori DC, Burton DR, Schief WR, Silvestri G, Ward AB
JournalNat Commun
Volume12
Issue1
Pagination4817
Date Published2021 Aug 10
ISSN2041-1723
KeywordsAIDS Vaccines, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibody Formation, Cryoelectron Microscopy, env Gene Products, Human Immunodeficiency Virus, Epitopes, Glycosylation, HIV Antibodies, HIV Infections, HIV-1, Humans, Macaca mulatta, Models, Molecular, Protein Conformation
Abstract

Engineered ectodomain trimer immunogens based on BG505 envelope glycoprotein are widely utilized as components of HIV vaccine development platforms. In this study, we used rhesus macaques to evaluate the immunogenicity of several stabilized BG505 SOSIP constructs both as free trimers and presented on a nanoparticle. We applied a cryoEM-based method for high-resolution mapping of polyclonal antibody responses elicited in immunized animals (cryoEMPEM). Mutational analysis coupled with neutralization assays were used to probe the neutralization potential at each epitope. We demonstrate that cryoEMPEM data can be used for rapid, high-resolution analysis of polyclonal antibody responses without the need for monoclonal antibody isolation. This approach allowed to resolve structurally distinct classes of antibodies that bind overlapping sites. In addition to comprehensive mapping of commonly targeted neutralizing and non-neutralizing epitopes in BG505 SOSIP immunogens, our analysis revealed that epitopes comprising engineered stabilizing mutations and of partially occupied glycosylation sites can be immunogenic.

DOI10.1038/s41467-021-25087-4
Alternate JournalNat Commun
PubMed ID34376662
PubMed Central IDPMC8355326
Grant ListUM1 AI144462 / AI / NIAID NIH HHS / United States
UM1 AI100663 / AI / NIAID NIH HHS / United States
P51 OD011132 / OD / NIH HHS / United States
UL1 TR001442 / TR / NCATS NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
R01 AI136621 / AI / NIAID NIH HHS / United States
F31 AI131873 / AI / NIAID NIH HHS / United States
P30 AI036214 / AI / NIAID NIH HHS / United States
P01 AI110657 / AI / NIAID NIH HHS / United States
U42 OD011023 / OD / NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587